Merck KGaA and Pfizer Terminates P-III JAVELIN Ovarian PARP 100 Study for Advanced Ovarian Cancer
Merck KGaA Collaborates with GenScript for the Expansion of Cell and Gene Therapies in China
Shots:
- The termination is based on P-III JAVELIN Ovarian PARP 100 study (B9991030) results assessing Bavencio (avelumab) + CT followed by avelumab + Talzenna (talazoparib) vs PBO in 9,000 patients with locally advanced or metastatic ovarian cancer
- The termination is due to its third failure with unmet degree of benefit observed with avelumab in ovarian cancer responding to its discontinuation & approval of AstraZeneca’s PARP Lynparza in ovarian cancer
- Bavencio (avelumab) is a mAb targeting PD-L1 protein while blocking PD-L1 interaction with PD-1 receptor. Talzenna (talazoparib) is a PARP inhibitor used in treatment of BRCA mutated breast cancer. In November 2014, Merck & Pfizer collaborated to co-develop & co-commercialize avelumab
Click here to read full press release/ article | Ref: Merck KGaA | Image: Wikimedia Commons